Do you have probable Dementia with Lewy Bodies (DLB), Mild Cognitive Impairment with "high likelihood" DLB, or Parkinson's Disease Dementia (PDD)? You may be able to participate in an observational study to track your disease progression and promote future research.

we want to learn more about seizure activity while a patient with epilepsy is not seizing or is at "rest" using data from resting state intracranial EEG (rs-iEEG) and resting state functional MRI (rs-fMRI).

The purpose of the NC Registry for Brain Health is to establish a mailing list of people who are interested in learning about ongoing research studies in North Carolina that are designed to improve brain health and prevent conditions such as Alzheimer's disease (AD). Anyone interested in learning more about this ongoing research or to get involved in these types of studies, now or in the future, may join the NC Registry for Brain Health. Joining is easy and free! You must be 18 years of age or older to register. People with and without memory disorders are welcome.

The purpose of this project is to create and distribute a survey with the intent to collect data about the amount and quality of training critical care physicians receive regarding brain death (i.e., death by neurologic criteria). We are doing because teaching physicians about brain death is not standardized and the subject is complex.

This study will gather information about patients who are taking new medicines for Alzheimer's disease. We'll keep an eye on how these patients are doing in the long run, tracking things like how they're responding to treatment, what their overall health outcomes are like, and how safe these new treatments really are when used in the real world. The goal of this study is to get a better understanding of how these therapies actually work for a diverse group of people, not just the people who usually participate in clinical trials.

The objective of the registry is to create a cohort of patients with NMOSD. This registry will be used for future research, as well as improvements to the diagnosis, treatment, and understanding of NMOSD.

This study compares two dose strengths of a new epilepsy medicine to placebo for treatment of refractory focal onset epilepsy as measured by the change in 28-day average seizure frequency.

The purpose of this study is to characterize the natural history of DRPLA patients using a variety of clinical and biomarker modalities and to identify genetic factors, biomarkers, and clinical measures that could predict disease progression.

This clinical trial aims to understand how well ALXN-C5IT works over a long time. We want to see if it can prevent relapses and help with disability, walking, and vision. We also want to know how patients feel about their health while using ALXN-C5IT.

We are collecting cerebral spinal fluid (CSF) from Normal Pressure Hydrocephaly (NPH) patients to generate a biosample research repository. This repository will be used to research CSF biomarkers for Alzheimer's disease that may enhance our ability to detect and monitor Alzheimer's disease diagnoses and progression.